Corporate greed and medical complicity fueled a $250,000 drug

episode

The Podcast by KevinMD not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from The Podcast by KevinMD

Understanding the unseen role of back-to-school diagnostics 15 min · 20 Dec 2025

All episodes from The Podcast by KevinMD →

Report any issue

Source

Recorded02 Jan 2026

Publisherkevinmd.libsyn.com ↗

Handlerec:15044158

Show notes

Internal medicine and pulmonary physician Bharat Desai discusses his article "How Acthar Gel became a $250,000 drug." Bharat shares the shocking moment he realized an obsolete pituitary extract from 1952 was being sold for the price of a house. He explains how pharmaceutical companies exploited regulatory loopholes to reclassify a cheap animal derivative as a specialty biologic and effectively monopolize the market despite the existence of superior synthetic alternatives like prednisone. The conversation exposes the deep rot within the medical profession where key opinion leaders and institutions accepted industry funding to promote a physiological absurdity over evidence-based care. We must question how intellectual surrender allows corporate greed to exploit the very patients doctors are sworn to protect. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.